Secarna Pharmaceuticals is the leading independent European antisense oligonucleotide (ASO) company with a broad pipeline of innovative therapeutic programs in various stages of pre-clinical development and multiple disease indications. Applying its proprietary LNAplus™ platform, the company is generating molecules with significantly improved potency and a comprehensive safety profile against targets that are difficult to regulate or currently not druggable by conventional approaches. Using state-of-the-art bioinformatics (OligofyerTM), Secarna’s antisense molecules are designed and optimized to meet highest specificity and activity criteria. As a result, there is little to no need for lead optimization which significantly speeds up the discovery and development process compared to conventional therapeutic approaches. LNAplus™ is validated by ten commercial partnering transactions, such as with Evotec and Denali Therapeutics, and various successful in-house projects.

At Secarna, we are paving the path for a new generation of therapeutics to give patients hope for innovative treatment options, especially in difficult to treat indications. Our proprietary third-generation antisense oligonucleotide (ASO) platform LNAplusTM enables us to discover and develop novel antisense-ased therapies for challenging or currently undruggable targets. Our pipeline contains over 15 programs focusing on targets in therapeutic areas such as immuno- oncology, immunology, ophthalmology, as well as viral-, neurodegenerative-, fibrotic- and cardiometabolic diseases, where antisense- ased approaches can have clear benefits compared to other therapeutic modalities.